2. Search Result
Search Result
Results for "

CCNB1

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

1

Peptides

1

Natural
Products

3

Recombinant Proteins

10

Antibodies

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-114779
    N9-Isopropylolomoucine

    		CDK Cancer
    N9-Isopropylolomoucine is a mitotic cyclin dependent kinase (CDK) inhibitor. N9-Isopropylolomoucine targets CCNB 1/CDK1 and can be used for cancer research [1].
    N9-Isopropylolomoucine
  • HY-RS02118
    CCNB1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CCNB1 Human Pre-designed siRNA Set A contains three designed siRNAs for CCNB1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CCNB1 Human Pre-designed siRNA Set A
    CCNB1 Human Pre-designed siRNA Set A
  • HY-RS17545
    Ccnb1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ccnb1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ccnb1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ccnb1 Mouse Pre-designed siRNA Set A
    Ccnb1 Mouse Pre-designed siRNA Set A
  • HY-RS24004
    Ccnb1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Ccnb1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Ccnb1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Ccnb1 Rat Pre-designed siRNA Set A
    Ccnb1 Rat Pre-designed siRNA Set A
  • HY-P11028
    M1-20

    		CDK Cancer
    M1-20 is a CDK1 inhibitor. M1-20 promotes CDK1 ubiquitination by CUL4-DDB1-DCAF1 complexes and degradation through the proteasome pathway. M1-20 abolishes the formation of CDK1/CCNB1 complexes. M1-20 has significant anticancer activity of spontaneous breast cancer in FVB/N MMTV-PyVT mice model [1].
    M1-20
  • HY-162895
    NL13

    		Polo-like Kinase (PLK) Akt CDK Caspase Apoptosis Cancer
    NL13 is a Polo-like kinase 4 (PLK4) inhibitor with an IC50 value of 2.32 μM. NL13 can inhibit the viability of PC3 and DU145 prostate cancer cells, with IC50 values of 3.51 μM and 2.53 μM, respectively. NL13 can lead to the inactivation of the AKT signaling pathway by downregulating CCNB1/CDK1, inducing G2/M cell cycle arrest, and triggering apoptosis through the cleavage of caspase-9/caspase-3. In prostate cancer mice, NL13 can inhibit tumor growth [1].
    NL13
  • HY-RS02119
    CCNB1IP1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    CCNB1IP1 Human Pre-designed siRNA Set A contains three designed siRNAs for CCNB1IP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    CCNB1IP1 Human Pre-designed siRNA Set A
    CCNB1IP1 Human Pre-designed siRNA Set A
  • HY-N19821
    Gangaleoidin

    		DNA/RNA Synthesis Cancer
    Gangaleoidin is a FOXM1 inhibitor with an IC50 of 2.8 μM. Gangaleoidin inhibits interaction between FOXM1’s DNA-binding domain and target DNA sequence, downregulates FOXM1 and downstream target gene CCNB1 at the transcriptional level. Gangaleoidin suppresses proliferation of FOXM1-overexpressing breast cancer cells. Gangaleoidin can be used for the research of breast cancer [1] .
    Gangaleoidin
  • HY-181076
    FOXM1-IN-3

    		PI3K CDK Apoptosis Cancer
    FOXM1-IN-3 is a potent FOXM1 inhibitor. FOXM1-IN-3 downregulates FOXM1 expression at protein and mRNA levels, suppressing downstream effectors CCNB1 and CDC25. FOXM1-IN-3 induces G2/M cell cycle arrest and apoptosis in colorectal cancer cells. FOXM1-IN-3 inhibits colony formation and cell migration in colorectal cancer cells. FOXM1-IN-3 targets the cancer stem cell phenotype in colorectal cancer cells, reducing cancer stem cell marker expression. FOXM1-IN-3 reduces tumor growth in a zebrafish xenograft model. FOXM1-IN-3 can be used for the research of colorectal cancer [1].
    FOXM1-IN-3
  • HY-181769
    Anticancer agent 306

    		MMP Polo-like Kinase (PLK) CDK PAK Bcl-2 Family Caspase Apoptosis Cancer
    Anticancer agent 306 is a spiro tetramic acid derivative and a inhibitor of MMP1, MMP7 and PLK1. Anticancer agent 306 exerts antiproliferative activity against H1299, RKO and MCF-7 cells with IC50 values of 19.25 μM, 3.29 μM and 102.36 μM, respectively. Anticancer agent 306 can up-regulate p21 protein and down-regulate CCND1 and CCNB1 proteins to induce cell cycle arrest, regulate the expression of Bcl-2 and Bax to induce cell apoptosis. Anticancer agent 306 can down-regulate MMP1 and MMP7 proteins to inhibit tumor invasion and metastasis. Anticancer agent 306 can be used for the research of lung cancer, colorectal cancer, breast cancer [1].
    Anticancer agent 306

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: